Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Issue 6 (4th December 2018)

• Record Type: Journal Article
• Authors: Seneviratne, Martin G.; Bozkurt, Selen; Patel, Manali I.; Seto, Tina; Brooks, James D.; Blayney, Douglas W.; Kurian, Allison W.; Hernandez‐Boussard, Tina
• Is Part Of: Cancer. Volume 125:Issue 6(2019)
• Page Start: 943
• Page End: 951
• Publication Date: 2018-12-04
• Subjects: breast -- global health -- patient‐centered outcomes -- prostate -- real‐world evidence; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31895
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: The collection of patient‐reported outcomes (PROs) is an emerging priority internationally, guiding clinical care, quality improvement projects and research studies. After the deployment of Patient‐Reported Outcomes Measurement Information System (PROMIS) surveys in routine outpatient workflows at an academic cancer center, electronic health record data were used to evaluate survey completion rates and self‐reported global health measures across 2 tumor types: breast and prostate cancer. Methods: This study retrospectively analyzed 11, 657 PROMIS surveys from patients with breast cancer and 4411 surveys from patients with prostate cancer, and it calculated survey completion rates and global physical health (GPH) and global mental health (GMH) scores between 2013 and 2018. Results: A total of 36.6% of eligible patients with breast cancer and 23.7% of patients with prostate cancer completed at least 1 survey, with completion rates lower among black patients for both tumor types ( P < .05). The mean T scores (calibrated to a general population mean of 50) for GPH were 48.4 ± 9 for breast cancer and 50.6 ± 9 for prostate cancer, and the GMH scores were 52.7 ± 8 and 52.1 ± 9, respectively. GPH and GMH were frequently lower among ethnic minorities, patients without private health insurance, and those with advanced disease. Conclusions: This analysis provides important baseline data on patient‐reported global health in breast and prostate cancer. Demonstrating that PROs can be integrated into clinical workflows, this study shows that supportive efforts may be needed to improve PRO collection and global health endpoints in vulnerable populations. Abstract : Using real‐world evidence from routine clinical visits, this study provides baseline data on patient‐reported global health in breast and prostate cancer. Differences in survey completion rates highlight populations that may be underrepresented in routinely collected patient‐reported outcome surveys, and suggest the need for supportive efforts to improve their global health across the patient care journey.